Your browser doesn't support javascript.
loading
TERT promoter mutation in adult granulosa cell tumor of the ovary.
Pilsworth, Jessica A; Cochrane, Dawn R; Xia, Zhouchunyang; Aubert, Geraldine; Färkkilä, Anniina E M; Horlings, Hugo M; Yanagida, Satoshi; Yang, Winnie; Lim, Jamie L P; Wang, Yi Kan; Bashashati, Ali; Keul, Jacqueline; Wong, Adele; Norris, Kevin; Brucker, Sara Y; Taran, Florin-Andrei; Krämer, Bernhard; Staebler, Annette; van Meurs, Hannah; Oliva, Esther; Shah, Sohrab P; Kommoss, Stefan; Kommoss, Friedrich; Gilks, C Blake; Baird, Duncan M; Huntsman, David G.
Afiliación
  • Pilsworth JA; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
  • Cochrane DR; Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Xia Z; Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Aubert G; Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Färkkilä AEM; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Horlings HM; Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Yanagida S; Children's Hospital and Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Yang W; Department of Radiation Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lim JLP; Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Wang YK; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Bashashati A; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
  • Keul J; Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Wong A; Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Norris K; Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Brucker SY; Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Taran FA; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany.
  • Krämer B; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Staebler A; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
  • van Meurs H; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany.
  • Oliva E; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany.
  • Shah SP; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany.
  • Kommoss S; Tübingen University Hospital, Institute of Pathology, Tübingen, Germany.
  • Kommoss F; Department of Gynecology, Center for Gynecologic Oncology Amsterdam, Academic Medical Center, 1100 DD Amsterdam, The Netherlands.
  • Gilks CB; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Baird DM; Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Huntsman DG; Department of Computer Science, University of British Columbia, Vancouver, BC, Canada.
Mod Pathol ; 31(7): 1107-1115, 2018 07.
Article en En | MEDLINE | ID: mdl-29449679
ABSTRACT
The telomerase reverse transcriptase (TERT) gene is highly expressed in stem cells and silenced upon differentiation. Cancer cells can attain immortality by activating TERT to maintain telomere length and telomerase activity, which is a crucial step of tumorigenesis. Two somatic mutations in the TERT promoter (C228T; C250T) have been identified as gain-of-function mutations that promote transcriptional activation of TERT in multiple cancers, such as melanoma and glioblastoma. A recent study investigating TERT promoter mutations in ovarian carcinomas found C228T and C250T mutations in 15.9% of clear cell carcinomas. However, it is unknown whether these mutations are frequent in other ovarian cancer subtypes, in particular, sex cord-stromal tumors including adult granulosa cell tumors. We performed whole-genome sequencing on ten adult granulosa cell tumors with matched normal blood and identified a TERT C228T promoter mutation in 50% of tumors. We found that adult granulosa cell tumors with mutated TERT promoter have increased expression of TERT mRNA and exhibited significantly longer telomeres compared to those with wild-type TERT promoter. Extension cohort analysis using allelic discrimination revealed the TERT C228T mutation in 51 of 229 primary adult granulosa cell tumors (22%), 24 of 58 recurrent adult granulosa cell tumors (41%), and 1 of 22 other sex cord-stromal tumors (5%). There was a significant difference in overall survival between patients with TERT C228T promoter mutation in the primary tumors and those without it (p = 0.00253, log-rank test). In seven adult granulosa cell tumors, we found the TERT C228T mutation present in recurrent tumors and absent in the corresponding primary tumor. Our data suggest that TERT C228T promoter mutations may have an important role in progression of adult granulosa cell tumors.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Telomerasa / Tumor de Células de la Granulosa Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Mod Pathol Asunto de la revista: PATOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Telomerasa / Tumor de Células de la Granulosa Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Mod Pathol Asunto de la revista: PATOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Canadá